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D
endritic cells (DC) are leukocytes that, although
infrequently represented in their tissues of origin
(lymphoid and solid organs and epithelia), are cri-
tically important in immunophysiology (Bancher-
eau and Steinman, 1998; Banchereau et al, 2000).
The central importance of DC can be attributed to their unique
ability to function as antigen- presenting cells (APC) that can in-
itiate responses in na|«ve T cells, and to dictate the net outcome of
this interaction as it relates to the character of the immune re-
sponsess that ensue. DC in normal skin are comprised of epider-
mal Langerhans cells (LC) and dermal DC (DDC). In selected
in£ammatory conditions, several more recently described DC
subpopulations can be detected and may be relevant: plasmacy-
toid DC (PDC) and in£ammatory dendritic epidermal cells (IDEC)
(Wollenberg et al, 2002).
The various DC subpopulations in skin can be di¡erentiated
from each other (and from non-DC) using monoclonal anti-
bodies that react with a variety of cell surface and intracellular
molecules, including di¡erentiation antigens, major histocomo-
patibility (MHC) antigens, and costimulatory molecules (Short-
man and Liu, 2002). It is important to distinguish the di¡erent
types of skin DC because it is very likely that at least some sub-
populations of skin DC have distinct functional properties. By
inference, di¡erent skin DC may be di¡erentially involved in
the pathogenesis of individual skin diseases.
LC are distinguished from other DC by expression of the non-
MHC class I molecule CD1a, the intercellular adhesion molecule
E-cadherin, and the novel C-type lectin Langerin (Jakob and
Udey, 1999; Valladeau et al, 2000). Langerin localizes to Birbeck
granules, distinctive intracytoplasmic vesicles that have long been
pathognomonic for these cells, and is expressed on cell surfaces as
well. Like other DC, LC express the leukocyte (b2) integrin
CD11c and MHC class II antigens, and have the capacity to upre-
gulate a variety of costimulatory molecules (CD40, CD80, CD86,
CD58, and others). In normal skin, DDC can be di¡erentiated
from LC by their location, lack of CD1a, E-cadherin and Langer-
in expression, absence of Birbeck granules, and expression of
CD1b and CD1c.
In in£amed skin, several additional DC subpopulations have
been identi¢ed (Wollenberg et al, 2002). IDEC are CD1aþ ,
HLA-DRþ cells that can be di¡erentiated from LC by coexpres-
sion of high levels of the leukocyte integrin CD11b. PDC are dis-
tinguished from the other skin DC by a lack of CD11c expression
and by expression of CD123 as well as the recently described sur-
face marker BCDA-2. Like other skin DC, PDC express high
levels of MHC class II antigens and can be induced to express
costimulatory molecules.
ONTOGENYOF SKIN DENDRITIC CELLS
Information regarding skin DC ontogeny comes from in vitro ex-
periments in which DC with characteristics of the various subpo-
pulations are propagated in culture, in vivo experiments involving
adoptive transfer of putative precursor cells in mice, and corro-
borative data from patients who receive hematologic reconstitu-
tion during cancer therapy (Shortman and Liu, 2002). Like all
leukocytes, skin DC are ultimately derived from bone marrow
precursors. On the basis of cell surface markers, it has been deter-
mined that LC, DDC, and IEDC are most closely related to cells
of the myeloid lineage. Cells with characteristics of LC and DDC
have been derived from lineage-negative CD34þ precursors
in vitro: the former from cutaneous leukocyte antigen (CLA,
PSGL-1: an E-selectin ligand)-expressing cells and the latter from
CLA cells. In serum-free medium, propagation of LC-like cells
is absolutely dependent on the presence of low concentrations of
transforming growth factor-b (TGF-b) (Strobl et al, 1996). The
signi¢cance of this ¢nding is emphasized by studies of TGF-b
knockout mice that indicate that these mutant animals are devoid
of LC (Borkowski et al, 1996).
Identi¢cation of physiologic immediate precursors of LC (as
well as other skin DC) has been di⁄cult. Because there is consid-
erable plasticity in the DC lineage, it is possible that distinctive
skin DC subpopulations may have multiple immediate precur-
sors, or that cells may be derived from di¡erent precursor pools
under steady state (resting) conditions and in the setting of skin
in£ammation. In vitro data indicate that human peripheral blood
monocytes can acquire certain LC characteristics after treatment
with GM-CSF and TGF-b (Geissmann et al, 1998) or GM-CSF
and IL-15 (Mohamadzadeh et al, 2001). In addition, monocyte-
like CD14þ , Langerin þ cells can be recovered from normal
human skin and induced to di¡erentiate into LC-like (CD1aþ ,
E-cadherin þ , Langerin þ ) cells by culturing them withTGF-b
in vitro (Larregina et al, 2001).Very recent and compelling studies
in mice indicate that in the absence of skin in£ammation, epider-
mal LC are derived from radioresistant, long-lived, proliferating,
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local precursors (Merad et al, 2002). This characteristic distin-
guishes them from all other myeloid DC. In addition, it has been
determined that rapid recruitment of LC bone marrow^derived
precursors occurs during skin in£ammation. Whether or not
these latter cells bear any relationship to the IDEC described in
human skin remains to be determined.
PDC are distinct from the other skin DC both in surface phe-
notype (see above) and in in vitro growth requirements (Kadowaki
and Liu, 2002).Whereas propagation of myeloid DC is dependent
on, or is enhanced by, inclusion of GM-CSF in the media, PDC
survival and di¡erentiation in vitro is dependent on IL-3. It has
been suggested that PDC may be more closely related to lym-
phocytes than to myeloid cells.
FUNCTION OF SKIN DENDRITIC CELLS
The role that DC play as intercellular bridges between innate and
adaptive immune responses is well established (Banchereau and
Steinman, 1998; Banchereau et al, 2000; Janeway and Medzhitov,
2002). Immature members of the lineage (such as LC) are sta-
tioned at interfaces between the organism and the outside world
and are equipped with sensors that allow them to survey their
microenvironment and to respond to perturbations (Pulendran
et al, 2001). These sensors include a variety of cell surface proteins
that are involved in the recognition of pathogens and pathogen-
associated molecules or cell fragments (e.g., lectins, complement
and Fc receptors, CD36, and av-containing integrins) as well as
molecules that are required for cellular responses to these insults
(e.g., Toll-like receptors (TLR)) (Shizuo et al, 2001). After recog-
nition and ingestion of complex antigens, and coincident with
activation, DC degrade antigens into MHC class I and II binding
peptides, upregulate costimulatory molecule expression and cyto-
kine production, and translocate from epidermis to regional
lymph nodes where they interact with na|«ve T cells (Banchereau
et al, 2000). The ability of di¡erent types of DC to recognize and
respond to di¡erent external stimuli is determined by the cell
surface receptors that they express. Similarly, the outcome of the
interaction between DC and T cells is determined by levels of
MHC antigen-peptide complexes and costimulator molecules
that are expressed on DC surfaces and the levels and types of cy-
tokines that are produced. The selective expression of the non-
classical MHC class I antigens CD1a,b,c in addition to classical
MHC class I and II antigens is responsible for the ability of LC,
DDC, and IDEC to be e⁄cient stimulators of T cell responses to
mycobacteria-derived glycolipids (Porcelli and Modlin, 1999).
Exogenously acquired antigens is readily processed and pre-
sented to CD4 T cells in the context of MHC class II antigens.
Interestingly, exogenously acquired particulate antigen (including
that acquired from apoptotic cells) can be e⁄ciently acquired and
processed by DC for presentation to CD8 T cells via a process
termed ‘‘cross-presentation’’ (Heath and Carbone, 2001). There is
considerable interest in de¢ning the cell surface receptors that
play critical roles in apoptotic cell recognition and uptake and in
delineating the downstream events that ensue. There is also con-
siderable interest in identifying physiologic ligands for the myr-
iad of C-type lectins that are expressed by dendritic cells (Figdor
et al, 2002). One such lectin, mannan-binding DC-SIGN, has
been determined to interact with ICAM-3 (and ICAM-2), HIV-
associated gp120, and mycobacteria. By analogy, identi¢cation of
ligands for Langerin (Valladeau et al, 2000) may provide insights
into specialized functions of the skin DC subtype (LC) that selec-
tively expresses this protein.
Expression of di¡erent TLRs by di¡erent skin DC will deter-
mine whether of not they participate in responses to particular
noxious insults (Hornung et al, 2002; Kadowaki and Liu 2002).
Immature human myeloid DC contain mRNAs encoding TLRs
1, 2, 3, 4, 5, 6, 8, and 10, whereas PDC synthesize TLRs 1, 6, 7, 9,
and 10. Thus, engagement of TLR4 by LPS will activate myeloid
DC, and the IL-12 that is produced will promote TH1 (as com-
pared with TH2) development. Because PDC do not express
TLR4, they will not respond to LPS but can release IL-12 after
activation via theTLR9 ligand, bacteria-derived immunostimula-
tory (unmethylated CpG island^containing) DNA. PDC are also
distinguished from the other skin DC by producing prodigious
amounts of type I interferons in response to viral infection (Ka-
dowaki and Liu, 2002). The unique ability of PDC to produce
large amounts of type I interferons after viral challenge indicates
that are they are essential participants in antiviral immunity.
It was recently proposed that DC (including skin DC) may be
involved in maintenance of peripheral tolerance (Steinman and
Nussenzweig, 2002). Deletion of autoreactive T cells in the thy-
mus during embryologic development is incomplete, so central
tolerance does not insure protection from autoimmune disease.
The ‘‘rediscovery’’ of suppressor T cells, now termed ‘‘regulatory’’
T cells, has provided a plausible mechanism for maintenance of
peripheral tolerance (McHugh and Shevach, 2002; Shevach,
2002). In addition, de¢nition of the activation requirements of
regulatory T cells implicates immature DC as important partici-
pants in this immunoregulatory mechanism. Although immature
DC are not able to stimulate na|«ve T cells to develop into tradi-
tional CD4 or CD8 e¡ectors, they are e⁄cient stimulators of
CD4þ CD25þ regulatoryT cells that can in turn actively sup-
press development of e¡ector cells (Mahnke et al, 2002). In this
way a basal level of tra⁄cking of LC from skin to regional lymph
node, in the absence of an activating stimulus that would result in
increased expression of costimulatory molecules (Geissmann et al,
2002). This process would allow for chronic presentation of skin-
derived self antigens, such as those associated with apoptotic cells
that continually generated, to autoreactive regulatoryT cells, and
allows for maintenance of antigen-speci¢c unresponsiveness.
SKIN DENDRITIC CELLS ANDAUTOIMMUNITY
The role (or roles) of DC in development or propagation of
autoimmune diseases is (are) incompletely de¢ned. The ability
of activated DC to break tolerance to self antigens in the setting
of DC cancer vaccine trials in mice and in humans (Steinman
and Pope, 2002) and the emerging role for DC in the mainte-
nance of peripheral tolerance (Steinman and Nussenzweig, 2002)
suggest that DC are relevant, however. Further characterization of
the activation requirements of regulatoryTcells and identi¢cation
of external stimuli that subvert this process will provide addi-
tional insights and may well provide additional support for the
long-held concept that infectious diseases are important triggers
of autoimmune diseases.
For several reasons, it is tempting to implicate skin DC as par-
ticularly relevant to autoimmune disease pathogenesis. The fre-
quency with which skin is involved in autoimmune disease
indicates that skin antigens are important targets and suggests that
e¡ector autoimmune responses may well have been initiated in
skin-draining, regional lymph nodes. The recognition that blebs
of apoptotic cells are rich sources of autoantigens (Casciola-Rosen
et al, 1994) and that incident ultraviolet radiation causes keratino-
cyte apoptosis (Casciola-Rosen and Rosen, 1997) provides yet an-
other possible link between autoimmunity and skin. Although
the uptake of apoptotic cell-derived antigens by macrophages ty-
pically results in an anti-in£ammatory response characterized by
IL-10 and/or TGF-b production, in the absence of e⁄cient clear-
ance by macrophages, apopotic cells can clearly be immunogenic
(Rosen and Casciola-Rosen, 2001). In this instance, DC are
almost certainly the relevant APC and it is logical to assume that
LC or DDC (or both) may be able to ful¢ll this role. It has also
been suggested that PDC are relevant to autoimmune disease
pathogenesis, particularly systemic lupus erythematosus (SLE)
pathogenesis. PDC are frequently found in LE skin lesions (Far-
kas et al, 2001), and type I interferons, produced largely by PDC,
have been implicated as key players in this disease (Palucka et al,
2002).
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Increasingly, DC experts are turning their attention to elucida-
tion of the roles that DC play in disease pathogenesis and to de-
signing therapies that will translate increased understanding of
DC physiology into improved patient care. To date, e¡orts to de-
velop active immunotherapies for cancer and chronic infections
have been at the forefront (Steinman and Pope, 2002). As DC-
dependent mechanisms that are responsible for the avoidance of
unwanted autoreactivity become better de¢ned and as the me-
chanisms by which autoimmune diseases are triggered become
better understood, we can anticipate that novel DC-based treat-
ments for autoimmune diseases will be forthcoming.
Note: This brief treatise is not intended to be comprehensive.
The author apologizes in advance for omissions, both planned
and unintended. For in-depth treatment of the subject matter,
the interested reader should refer to one or more of the excellent
reviews that regularly appear (some of which are referenced here-
in) or the primary literature.
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